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Abstract
In this report, we describe the development of a transgenic mouse in which a rat probasin promoter (ARR2Pb) was
used to direct prostate specific expression of a constitutively active form of signal transducer and activator of tran-
scription 3 (i.e., Stat3C). ARR2Pb.Stat3C mice exhibited hyperplasia and prostate intraepithelial neoplasia (PIN) lesions
in both ventral and dorsolateral prostate lobes at 6 and 12 months; however, no adenocarcinomas were detected.
Theeffect of combined loss of PTENwas examinedby crossingARR2Pb.Stat3CmicewithPTEN
+/− nullmice. PTEN+/−
null mice on an ICR genetic background developed only hyperplasia and PIN at 6 and 12 months, respectively.
ARR2Pb.Stat3C × PTEN
+/− mice exhibited a more severe prostate phenotype compared with ARR2Pb.Stat3C and
PTEN+/− mice. ARR2Pb.Stat3C × PTEN
+/− mice developed adenocarcinomas in the ventral prostate as early as
6 months (22% incidence) that reached an incidence of 61% by 12 months. Further evaluations indicated that
phospho-Stat3, phospho-Akt, phospho-nuclear factor κB, cyclin D1, and Ki67 were upregulated in adenocarcinomas
from ARR2Pb.Stat3C × PTEN
+/− mice. In addition, membrane staining for β-catenin and E-cadherin was reduced.
The changes in Stat3 and nuclear factor κB phosphorylation correlated most closely with tumor progression. Collec-
tively, these data provide evidence that Stat3 and Akt signaling cooperate in prostate cancer development and pro-
gression and that ARR2Pb.Stat3C × PTEN
+/− mice represent a novel mouse model of prostate cancer to study
these interactions.
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Introduction
Signal transducers and activators of transcription (Stats) are a family
of latent transcriptions factors that transmit signals from the extracel-
lular surface of cells to the nucleus as part of the normal cellular re-
sponse to cytokines and growth factors (reviewed in references [1–3]).
Stats are involved in normal processes such as development, differ-
entiation, immune function, proliferation, survival, and epithelial-to-
mesenchymal transition (EMT) [1–8]. In addition, Stats have been
implicated in cell growth and survival during oncogenesis. In this re-
gard, constitutive activation of Stat3 has been observed in many hu-
man tumors including breast, prostate, melanoma, pancreas, ovarian,
colorectal, and brain (reviewed in references [5–9]). In prostate cancer
cell lines, Stat3 activation correlated with malignancy [10,11]. Inhibi-
tion of Stat3 in DU145 cells by antisense Stat3 oligonucleotides re-
sulted in growth inhibition and apoptosis [10]. Stat3 has also been
shown to be involved in tumor progression. Analysis of prostate ade-
nocarcinoma specimens revealed elevated levels of activated Stat3,
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and they were positively correlated with a more advanced stage of tu-
mors exhibiting higher Gleason scores [10]. Thus, Stat3 seems to be
involved in both proliferation and survival of prostate cancer cells
as well as prostate cancer progression. Our laboratory has also re-
cently shown that overexpression of a constitutively active form of
Stat3 leads to rapid progression of skin tumors associated with altered
expression of markers for EMT [12,13]. These data further support a
role for Stat3 in tumor progression.
Stat3 has been reported to regulate several transcription factors im-
plicated in cell lineage determination and differentiation. In this re-
gard, Stat3 regulates transcription factors such as Twist and the Snail
family members Snail (Sna1) and Slug (Sna2) that have been shown
to regulate E-cadherin expression during EMT [14–18]. Using an
androgen-resistant prostate cancer cell (ARCap) model of EMT, Zhau
et al. [19] demonstrated a link between LIV-1, a downstream target
of Stat3, and EMT. The authors concluded that signaling through
Stat3–Snail–LIV-1 resulted in an increased expression of receptor
activator of nuclear factor κB (NF-κB) ligand, which facilitates bone
metastases during prostate cancer progression. These studies further
support the hypothesis that activated Stat3 may play a role in progres-
sion of epithelial cancers, including prostate cancer.
Tumor suppressor gene phosphatase and tensin homolog (PTEN), a
lipid and protein phosphatase, is a negative regulator of AKT [20] and
loss of PTEN function leads to constitutive activation of Akt [21–24].
Loss of one PTEN allele is a high-frequency event in prostate cancer,
observed in up to 70% to 80% of primary tumors [24–27]. Homo-
zygous inactivation of PTEN is associated with advanced disease and
metastasis [28,29]. PTEN heterozygous null mice (PTEN+/− mice)
develop prostate intraepithelial neoplasia (PIN) with a variable pene-
trance varying from 40% to 50% [30–32] to 90% [33]. Lesions devel-
op mainly in the anterior and dorsolateral prostate but are also observed
in the ventral prostate. Progression to adenocarcinoma is normally not
observed in PTEN+/− mice, possibly related to age-dependent morbid-
ity due to the high incidence of thymic lymphomas that occur in these
mice. In contrast, conditional PTEN knockout mice with complete loss
of PTEN in the prostate develop invasive prostatic carcinoma but with
an extended latent period [34,35]. It has been suggested that genetic
background and/or modifier genes may influence the development of
lesions in PTEN-haploinsufficient animals [33]. In this regard, PTEN
locus heterozygosity on a C57BL/6 genetic background seems to
be fully penetrant for the development of prostate adenocarcinoma
[36]. Inactivation of PTEN in combination with other mutations
can promote prostate cancer progression in transgenic mice [37–40].
Studies in cancer cell lines, including prostate cancer cell lines,
have shown an interaction between Stat3 and PTEN signaling path-
ways [41–46].
In this study, we describe the development and characterization of
a transgenic mouse model (ARR2Pb.Stat3C) in which a rat com-
posite probasin promoter (ARR2Pb) [47] was used to target prostate-
specific expression of an activated form of Stat3 protein (Stat3C)
[48]. We show that constitutive activation of Stat3 resulted in a path-
ologic phenotype in the prostate with the development of hyperplasia
and PIN. In addition, through the generation of compound trans-
genic mice, we demonstrate that activation of Stat3 coupled with loss
of PTEN (ARR2Pb.Stat3C × PTEN
+/− mice) exacerbated the pros-
tate phenotype. Male ARR2Pb.Stat3C × PTEN
+/− mice developed
low-grade and high-grade PIN as well as adenocarcinomas primarily
in the ventral prostate. From these studies, we conclude that cooper-
ation between Stat3 and Akt signaling pathways results in the pro-
gression from preneoplastic to neoplastic changes in the prostate of
mice, resulting in the development of invasive carcinomas.
Materials and Methods
Generation of Transgenic Mice
ARR2Pb.Stat3C transgenic line. The Stat3C complementary
DNA (cDNA; courtesy of J. Bromberg) was ligated into a plasmid
vector (pPB.129, courtesy of R. Mutasik) between the β-globin intron
sequence and the polyadenylation signal. Expression of the Stat3C
cDNA was targeted by the composite androgen-responsive probasin
(ARR2Pb) promoter to the prostate luminal epithelial cells. The re-
combinant vector (ARR2Pb.Stat3C) was excised, purified using the
Wizard SV DNA purification kit (Promega, Madison, WI), and used
to generate transgenic founders on a FVB genetic background. Three
different reactions were performed to verify full-length transgene in-
sertion by polymerase chain reaction (PCR) using specific primers.
The first reaction was performed to amplify the β-globin intron as re-
ported previously [8], Stat3-GCC GCC GTA GTG ACA GAG AA
(forward) and GGC AGC AAC ATC CCC AGA GT (reverse), the
second reaction to amplify the Stat3C transgene, and the third one
to amplify a fragment that contained the β-globin intron and the
Stat3C transgene (β-globin intron 5′ primer and STAT3-C 3′ primer).
Transgenic F1 progeny were identified by PCR amplification of geno-
mic DNA using primers for the β-globin intron.
ARR2Pb.Stat3C × PTEN
+/− mice. The PTEN+/− line was orig-
inally received on the C57BL/6 genetic background [30]. Successive
backcrosses onto ICR were performed for 10 generations before
conducting this study. Mice carrying the PTEN deletion were iden-
tified by PCR of genomic DNA using the following primers: Pten
(exon 5)—AGA CCA TAA CCC ACC ACA GC (forward); Pten
(exon 5)—TAG GGC CTC TTG TGC CTT TA (reverse), wild-type;
R1 Neo 288 (PTEN mutant)—GTG CAA TCC ATC TTG TTC
AAT GGC CG (reverse) to give amplification products of ∼200 bp
for the wild-type and ∼625 bp for the knockout. Littermates of the
appropriate genotype were used for comparison in all studies. For all
the studies, mice were housed in suspended polycarbonate cages or
individually ventilated cages (Lab Products, Maywood, NJ) on auto-
claved hardwood bedding at room temperature of 20 to 22°C, relative
humidity of 60% to 70% and 14/10-hour light-dark cycle.
Histologic Analysis
For histologic analysis, the male reproductive tract was removed
intact from ARR2Pb.Stat3C, PTEN
+/−, ARR2Pb.Stat3C × PTEN
+/−,
and nontransgenic littermates at 6 and 12 months, fixed in 10% for-
malin, embedded in paraffin, and transversely sectioned. Sections
of 4 μm were stained with hematoxylin and eosin (H&E), and im-
munohistochemistry (IHC) was performed on paraffin-embedded
prostate tissue sections using primary antibodies against phospho-
Stat3 (Tyr705, 1:50), phospho-Akt (Ser473, 1:50), phospho-NF-κB
(p65, 1:50; Cell Signaling Technology, Beverly, MA), Flag-tag (for
Stat3C, 1:50; Sigma-Aldrich, St Louis, MO), E-cadherin (1:50),
Ki67 (1:50), Akt (1:100; Santa Cruz Biotechnology, Inc, Santa Cruz,
CA), and β-catenin (BD Biosciences, San Jose, CA). Antibodies
were detected with biotinylated secondary antibodies, followed by
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peroxidase-conjugated avidin/biotin (Vectastain ABC Kit; Vector Labo-
ratories, Burlingame, CA) and DAB substrate (Dako, Carpinteria, CA).
Western Blot Analysis
Individual prostate lobes were excised and homogenized in lysis
buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM
β-glycerophosphate, protease inhibitor cocktail [Sigma-Aldrich]). Fifty
micrograms of cell lysates was electrophoretically separated on 7%
to 10% SDS-PAGE and transferred onto nitrocellulose membrane
(BioRad Laboratories, Hercules, CA). Transfer was performed at 30 V
overnight. After blocking with 5% skim milk in phosphate-buffered
saline containing 0.1% Tween, the membranes were incubated with
antibodies against: flag-tag (for Stat3C, 1:1000; Sigma-Aldrich), Stat3
(1:1000), phospho-Stat3 (1:1000, Tyr705 and Ser727), Akt (1:1000)
and phospho-Akt (1:500, Thr308 and Ser473; Cell Signaling Technol-
ogy), and β-actin (mouse monoclonal, 1:4000; Sigma-Aldrich). Pro-
tein bands were detected using enhanced chemiluminescence (Pierce
Biotechnology, Inc, Rockford, IL). Protein quantification was then
determined using an imaging system (Alpha Innotech, Cell Biosciences,
Santa Clara, CA). The relative density of each protein band was nor-
malized to the density of the corresponding β-actin band, and where
possible, phosphorylated proteins were presented as the ratio of phos-
phorylated and total protein.
Statistical Analyses
The incidence of prostate lesions shown in Table 1 was analyzed
using the Fisher exact test. Statistical significance of data from West-
ern blot analyses was evaluated using Wilcoxon rank-sum test. Sig-
nificance was set in both cases at P ≤ .05.
Results
ARR2Pb.Stat3C mice were generated on an FVB/N genetic back-
ground. A diagram of the DNA construct containing Stat3C cDNA
used to generate the mice is shown in Figure 1A. Founders were
screened for transgene insertion by PCR. Five founders (A, B, C,
D, and E) containing the transgene were used to establish transgenic
lines as described in Materials and Methods (Figure 1B). All but
Table 1. Distribution and Incidence of Prostate Lesions.
Group Ventral Prostate Dorsolateral Prostate
Hyperplasia PIN* AC Hyperplasia PIN AC
At 6 mo
ARR2Pb.Stat3C 14/16 (88%) 5/16 (31%) 0/16 (0%) 9/16 (56%) 3/16 (18%) 0/16 (0%)
PTEN+/− 8/8 (100%) 4/8 (50%) 0/8 (0%) 7/8 (87%) 1/8 (12%) 0/8 (0%)
ARR2Pb.Stat3C × PTEN
+/− 9/9 (100%) 6/9 (67%) 2/9 (22%) 9/9 (100%) 4/9 (44%) 0/9 (0%)
At 12 mo
ARR2Pb.Stat3C 25/25 (100%) 17/25 (68%) 0/25 (0%) 16/25 (61%) 11/25 (42%) 0/25 (0%)
PTEN+/− 7/7 (100%) 5/7 (71%) 0/7 (0%) 7/7 (100%) 4/7 (57%) 0/7 (0%)
ARR2Pb.Stat3C × PTEN
+/− 18/18 (100%) 17/18 (94%)† 11/18 (61%)‡ 18/18 (100%) 12/18 (66%) 0/18 (0%)
*AC indicates adenocarcinoma; PIN, prostatic intraepithelial neoplasia.
†Incidence of PIN was significantly different from the incidence observed in either single transgenic line (P = .030; Fisher exact test).
‡Incidence of AC was significantly different from the incidence observed in either single transgenic line (P = .0001; Fisher exact test).
Figure 1. Verification of ARR2Pb.Stat3C transgenic founders and transgene expression. (A) Diagram of construct used to generate
ARR2Pb.Stat3C founders. (B) Verification of presence of transgene by PCR analysis using sequence specific primers. (C) Western blot
analysis of protein expression of Stat3C (using antibodies against the flag-tag) in lysates prepared from ventral and dorsolateral prostate.
Protein was normalized to β-actin.
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founder C passed the transgene. Protein was isolated from different
lobes of the prostate of transgenic mice derived from the F1 genera-
tion of the four founders that passed the transgene, and Western blot
analyses confirmed the highest level of transgene expression in mice
derived from founder E (Figure 1C ). Mice derived from founder E
(i.e., line E mice) were used for all subsequent experiments.
For the morphologic characterization of the prostate, the intact
reproductive tract was removed from hemizygous ARR2Pb.Stat3C
male mice at both 6 (n = 16) and 12 (n = 21) months and analyzed.
Histologic diagnoses of the prostate lesions were in accordance with
the Consensus Report from the Bar Harbor Meeting of the Mouse
Models of Human Cancer Consortium Pathology Committee [49].
As shown in Figure 2, constitutive expression of activated Stat3 resulted
in a prostate phenotype characterized by hyperplasia and PIN lesions
that were evident by 6 months. At 12 months, there was a 100% in-
cidence of hyperplasia in the ventral lobe and a 61% incidence in
the dorsolateral lobe. At 6 and 12 months, PIN lesions were also
observed in both the ventral and dorsolateral prostate. In this regard,
at 12 months, there was a 68% and 42% incidence of PIN lesions,
respectively. Figures W1 and W2 show additional low- and higher-
magnification H&E-stained sections of ventral prostate lesions from
12-month-old ARR2Pb.Stat3C mice. PIN lesions exhibited a cribri-
form pattern. In addition, cells with karyomegaly, karyocytomegaly,
nuclear atypia with apical localization, and chromatin condensation were
observed. The presence of one or more prominent nucleolus was also ob-
served. To date, the development of invasive adenocarcinoma has not
been observed in the ARR2Pb.Stat3C transgenic male mice on either
the FVB/N or mixed FVB/N/ICR genetic background (see below).
Given that loss or inactivation of PTEN is a common occurrence
in human prostate cancer [24–27] and that homozygous inactivation
of PTEN is associated with advanced disease and metastasis [28,29],
we examined the effect of loss of PTEN on the development of pros-
tate lesions in ARR2Pb.Stat3C mice. Hemizygous ARR2Pb.Stat3C
mice were bred to heterozygous PTEN+/− mice (ICR background) to
generate ARR2Pb.Stat3C × PTEN
+/−, ARR2Pb.Stat3C and PTEN
+/−
offspring, which were then evaluated at 6 and 12 months. Note that
all mice for these comparisons were littermates with the same mixed
genetic background. The reproductive tract was removed and processed
as described above for subsequent histologic analyses. PIN (66%)
and adenocarcinoma (22%) were observed in the ventral prostate of
ARR2Pb.Stat3C × PTEN
+/− mice as early as 6 months. By 12 months,
the incidence of PIN had increased to 94% (17/18) and the incidence
of adenocarcinoma was 61% (11/18) in the ventral prostate. In con-
trast, adenocarcinomas were not observed in either ARR2Pb.Stat3C or
Figure 2. Characterization of prostate lesions in ARR2Pb.Stat3C male mice. H&E-stained sections and staining for transgene expression
using an antibody to the flag-tag are shown in representative sections of the ventral and dorsolateral prostate lobes of ARR2Pb.Stat3C
transgenic male mice. Prostates were harvested from nontransgenic (control) and ARR2Pb.Stat3C male mice at 6 or 12 months. At
6 months, prostate tissue of ARR2Pb.Stat3C transgenic mice appeared relatively normal with some areas of hyperplasia. By 12 months,
lesions were more aggressive with more pronounced epithelial tufting and the development of PIN. Flag-tag expression was detected in
normal (active) glands and in hyperplastic glands of the ARR2Pb.Stat3C prostate, although transgene expression appeared to be lower in
PIN lesions in either prostate lobe. It should also be noted that the level of transgene expression in the dorsolateral prostate lobe was
consistent with the Western blot data showing lower expression of the transgene versus the level observed in the ventral prostate lobe.
Magnifications, ×20.
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PTEN+/− littermates of the same age. Representative lesions from the
different genotypes are shown in Figure 3 ( panel A: 6 months; panel B:
12 months), and the overall incidence of prostate lesions for each
genotype at 6 and 12 months is summarized in Table 1. Note that
all adenocarcinomas were detected in the ventral prostate of the
ARR2Pb.Stat3C × PTEN
+/− mice. Figures W3 and W4 show H&E
staining of additional examples of adenocarcinomas (with higher mag-
nifications) in the double transgenic mice. Note a clear membrane dis-
ruption of the prostate glands, stromal invasion, hemorrhage in some
areas of the invaded tissue, as well as vascularization inside of the af-
fected glands. Figure W5 shows staining for K14 which is expressed in
the basal cells of the normal glands (Figure W5A). In adenocarcinomas
(Figure W5B), some cells with K14 expression were also observed in
the surrounding stroma. Figure W5, C to E , show laminin staining,
clearly demarking areas of glandular membrane disruption.
IHC analyses were performed to assess the levels of phospho-Stat3,
phospho-Akt, and cyclin D1 in lesions from the ARR2Pb.Stat3C,
PTEN+/−, and ARR2Pb.Stat3C × PTEN
+/− offspring (Figure 4).
Phospho-Stat3 was undetectable in PIN of ARR2Pb.Stat3C mice,
and although phospho-Stat3 staining was clearly evident in PIN le-
sions of PTEN+/− mice, in this case, expression was limited to the
cytoplasm. In contrast, clear nuclear staining of phospho-Stat3 was
evident in the PIN lesions from the ARR2Pb.Stat3C × PTEN
+/−
mice, indicating activation and nuclear translocation of Stat3 in these
lesions. IHC analyses of adenocarcinomas in the ARR2Pb.Stat3C ×
PTEN+/− mice revealed intense nuclear staining of phospho-Stat3
(Figure 4). Total Stat3 staining was mainly observed in the cytoplasm
of the PIN lesions in ARR2Pb.Stat3C mice. A similar although
slightly more intense staining pattern for total Stat3 was observed in
the PTEN+/− mice and in the PIN and AC of the ARR2Pb.Stat3C ×
PTEN+/− mice. Phospho-Akt staining was undetectable in PIN that
developed in either the ARR2Pb.Stat3C or the PTEN
+/− mice; how-
ever, clear staining of phospho-Akt was observed in the PIN of the
ARR2Pb.Stat3C × PTEN
+/−, and more intense staining was observed in
Figure 3. Characterization of prostate lesions in ARR2Pb.Stat3C × PTEN
+/−male mice. (A) Representative lesions in the ventral prostate of
the ARR2Pb.Stat3C, PTEN
+/−, and ARR2Pb.Stat3C × PTEN
+/− male mice at 6 months. Hyperplasia and PIN lesions developed in the
ARR2Pb.Stat3C and PTEN
+/− lines, whereas in the ARR2Pb.Stat3C × PTEN
+/− transgenic mice, adenocarcinomas (AC) were observed.
(B) Additional examples of hyperplasia and PIN (top left) and AC (remaining panels) in the ventral prostate of the ARR2Pb.Stat3C × PTEN
+/−
mice at 12 months. ACs were characterized by disruption of the basement membrane, destructive local invasion, extension into the loose
connective tissue, and foci of neovascularization.
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the adenocarcinomas, particularly at the membrane. Total Akt staining
was mainly observed in the cytoplasm of PIN lesions in both
ARR2Pb.Stat3C and PTEN
+/− mice, whereas staining was slightly in-
creased in PIN and AC of the ARR2Pb.Stat3C × PTEN
+/− mice
(again, see Figure 4). Cyclin D1 immunostaining generally followed
the pattern of phospho-Stat3, that is, nuclear staining of cyclin D1
was observed in the PIN of ARR2Pb.Stat3C × PTEN
+/− mice and
more intense staining was observed in adenocarcinomas. In light of
the finding of significant nuclear staining for phospho-Stat3 in adeno-
carcinomas of ARR2Pb.Stat3C × PTEN
+/− mice, further analyses were
performed. As shown in Figures W6 and W7, the expression of the
transgene in ventral prostate of ARR2Pb.Stat3C mice (Stat3C using
antibody to the flag-tag) revealed its presence and both cytoplasmic
and nuclear localization in normal (active) glands and hyperplasia.
However, Stat3C staining appeared lower in PIN and adenocarci-
nomas from ARR2Pb.Stat3C × PTEN
+/− mice. In addition, little or
no nuclear staining was evident. In contrast, phospho-Stat3 staining
was mostly cytoplasmic in normal (active) and hyperplastic glands,
but nuclear staining was evident in PIN and especially adenocarci-
nomas. Collectively, these results suggest that transgene expression
diminished with tumor progression, whereas activation of Stat3
(presumably endogenous Stat3) increased and was associated with
tumor progression in ARR2Pb.Stat3C × PTEN
+/− mice.
In further experiments, Western blot analyses were performed to
confirm the phosphorylation status of Stat3 and Akt in the ventral
prostate of the ARR2Pb.Stat3C × PTEN
+/− mice (Figure 5). For these
analyses, ventral prostate tissue was collected and pooled for each geno-
type at 6 months. Again, all mice used for these experiments were lit-
termates of similar mixed genetic background. Interestingly, the level
of total Stat3 was comparable for each genotype, that is, similar to the
level observed in the control group; however, analysis of phospho-Stat3
(both Tyr705 and Ser727) revealed that the ARR2Pb.Stat3C × PTEN
+/−
mice had significantly higher (P < .05) levels of Stat3 phosphorylation
at both sites relative to the other genotypes or nontransgenic mice. The
level of total Akt protein was also relatively similar in all the groups;
however, significant differences were observed in the levels of phos-
phorylated Akt at both the Thr308 and Ser473 phosphorylation sites.
In this regard, increases in phosphorylation at both sites were observed
Figure 4. Status of Stat3, phospho-Stat3, Akt, phospho-Akt and Cyclin D1 in prostate of ARR2Pb.Stat3C × PTEN
+/− mice. IHC analyses
of the ventral prostate in the parental lines (ARR2Pb.Stat3C and PTEN
+/−) and compound transgenic mice (ARR2Pb.Stat3C × PTEN
+/−).
All mice were aged 6 months at the time of tissue collection. IHC staining of prostate sections was performed using antibodies against
Stat3, phospho-Stat3 (Tyr705), Akt, phospho-Akt (Ser473), and cyclin D1.
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in the ARR2Pb.Stat3C, PTEN
+/−, and the ARR2Pb.Stat3C × PTEN
+/−
groups relative to the level observed in the control group (P < .05) with
the highest levels observed in the PTEN+/− and the ARR2Pb.Stat3C ×
PTEN+/− mice. The levels of Akt phosphorylation (both sites) between
the PTEN+/− and ARR2Pb.Stat3C × PTEN
+/− were not significantly
different (P > .05). Interestingly, protein lysates from ventral prostate
of ARR2Pb.Stat3C mice showed a significant increase (P < .05) in Akt
phosphorylation (both sites) compared with control mice. Thus, over-
expression of a constitutively active Stat3 either directly or indirectly
led to increased phosphorylation of Akt. Overall, these results are consis-
tent with the IHC analyses in which phospho-Stat3 and phospho-Akt
were highly expressed in the adenocarcinomas of the ARR2Pb.Stat3C ×
PTEN+/− mice. Based on the IHC and Western blot analyses, the level
of phospho-Stat3 seemed to correlate most closely with the transition
from PIN to adenocarcinomas in ARR2Pb.Stat3C × PTEN
+/− mice.
In light of the enhanced progression of prostate tumors observed
in the ARR2Pb.Stat3C × PTEN
+/− mice, we examined the expression
of several other markers in ventral prostate including β-catenin,
E-cadherin, and Ki67 in normal tissue, hyperplasia, PIN lesions,
and adenocarcinomas by IHC.We also examined the phosphorylation
status of NF-κB. The results of these analyses are shown in Figures 6
and 7. As expected, Ki67 expression was low in normal glands,
whereas nuclear Ki67 expression was slightly increased in hyperplasia
(Figure 6). In contrast, a significant increase in nuclear Ki67 was ob-
served in PIN and especially adenocarcinomas. Note that Ki67 ex-
pression in the adenocarcinomas not only was present inside of
the affected glands but also was observed in cells in the surround-
ing stroma. Immunostaining of hyperplastic tissues and PIN lesions
for progression markers (i.e., β-catenin and E-cadherin) was similar
to normal tissue (Figure 6). In contrast, the expression pattern of
β-catenin and E-cadherin in adenocarcinomas was irregular. In some
areas, there was clear loss of membrane staining for both β-catenin
and E-cadherin.
As shown in Figure 7, phosphorylation of NF-κB (p65) was found in
only a few scattered cells in the ventral prostate of the ARR2Pb.Stat3C
and PTEN+/− mice. In ARR2Pb.Stat3C × PTEN+/− mice, there also
were only few a scattered cells staining for nuclear phospho-NF-κB
in nontumor areas. In contrast, there was a significant increase in nu-
clear staining of phospho–NF-κB (p65) in the adenocarcinomas of
these mice (Figure 7, A and B). Additional adenocarcinomas from ven-
tral prostate of the ARR2Pb.Stat3C × PTEN
+/− mice were stained for
phospho–NF-κB (Figure W8). As shown, all samples including those
shown in Figure 7 (7/7 total, 100%) showed intense nuclear staining
for phospho–NF-κB (p65). Collectively, the disruption of β-catenin
Figure 5.Western blot analyses of phosphorylation status and expression of Stat3 and Akt in ventral prostate. (A) Western blot analyses
of protein lysates prepared from pooled prostate tissues from nontransgenic (control), ARR2Pb.Stat3C, PTEN
+/−, and ARR2Pb.Stat3C ×
PTEN+/− mice using antibodies against Stat3, phospho-Stat3 (Tyr705 and Ser727), Akt, and phospho-Akt (Thr308 and Ser473). Mice were
aged 6 months at the time of tissue collection. (B) Quantitation of protein levels by densitometry. Protein amounts were normalized
using actin and levels of phosphorylated proteins are presented as the ratio of phosphorylated and total protein. (B, top panel) *Signif-
icantly different from control, ARR2Pb.Stat3C, and PTEN
+/− groups (P < .05, Wilcoxon rank-sum test). (B, bottom panel) aSignificantly
different from ARR2Pb.Stat3C, PTEN
+/−, and ARR2Pb.Stat3C × PTEN
+/− groups (P < .05, Wilcoxon rank-sum test). bSignificantly dif-
ferent from control, PTEN+/−, and ARR2Pb.Stat3C × PTEN+/− groups (P < .05, Wilcoxon rank-sum test). cSignificantly different from
control and ARR2Pb.Stat3C groups (P < .05, Wilcoxon rank-sum test).
dSignificantly different from control and ARR2Pb.Stat3C groups
(P < .05, Wilcoxon rank-sum test).
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and E-cadherin membrane expression and the increased expression of
phospho-NF-κB also seemed to be associated with the development
of adenocarcinomas and correlated with the enhanced tumor progres-
sion seen in the ARR2Pb.Stat3C × PTEN
+/− mice.
Discussion
In the current study, we have described the development and char-
acterization of a new transgenic mouse model, the ARR2Pb.Stat3C
mice, in which the long probasin promoter (ARR2Pb) was used to tar-
get prostate specific expression of an activated form of Stat3 (Stat3C).
We show that expression of this constitutively active form of Stat3 re-
sulted in a pathologic phenotype in the prostate of these mice charac-
terized by development of hyperplasia and PIN. Furthermore, the
severity and frequency of the lesions increased with age, although
adenocarcinomas were not observed even in mice 1 year or older. In
contrast, we showed that activation of Stat3 coupled with loss of
PTEN (i.e., ARR2Pb.Stat3C × PTEN
+/− mice) exacerbated the pros-
tate phenotype compared with either ARR2Pb.Stat3C or PTEN
+/−
littermates harboring a single genetic alteration. In this regard, the
ARR2Pb.Stat3C × PTEN
+/− mice developed a stronger pathologic
phenotype particularly in the ventral prostate. Hyperplasia (100%),
PIN (67%), and adenocarcinomas (22%) were observed in the
ARR2Pb.Stat3C × PTEN
+/− mice as early as 6 months. At 12 months,
hyperplasia was again observed in 100% of the mice, whereas PIN
(94%) and adenocarcinomas (61%) were observed at a higher inci-
dence again primarily in the ventral prostate. Thus, cross talk between
Stat3 and Akt signaling pathways resulted in the progression from pre-
neoplastic to neoplastic changes, with the outcome the development of
locally invasive adenocarcinomas. IHC evaluation of adenocarcinomas
from the ARR2Pb.Stat3C × PTEN
+/− mice showed elevated phospho-
Stat3 and phospho-Akt staining. In addition, Western blot analyses of
protein lysates from ventral prostate confirmed high levels of phospho-
Stat3 and phospho-Akt proteins. More intense nuclear staining of
cyclin D1 and Ki67 was also observed in adenocarcinomas denoting
a high proliferation rate of these lesions. Adenocarcinomas also ex-
hibited intense nuclear staining for phospho-NF-κB (p65). Finally,
β-catenin and E-cadherin expression was disrupted in adenocarci-
nomas consistent with the increased progression of prostate lesions.
As noted above, we found that expression of a constitutively active
Stat3 (Stat3C) in mouse prostate produced exclusively premalignant
lesions. Although expression of the transgene was detected in the pros-
tate before development of premalignant lesions in ARR2Pb.Stat3C
mice, transgene expression seemed to be reduced somewhat in PIN
lesions (Figure 2). This reduced expression may have limited the pro-
gression of PIN to adenocarcinoma in ARR2Pb.Stat3C mice. Thus,
only in the compound transgenic mice did we observe progression of
PIN to adenocarcinoma. In ARR2Pb.Stat3C × PTEN
+/− mice, trans-
gene expression also seemed to be reduced in both PIN and adeno-
carcinomas (Figures W6 and W7). Analysis of phospho-Stat3 levels
by both immunohistochemistry andWestern blot revealed similar levels
of both Ser727 and Tyr705 phosphorylation in ventral prostate tissue of
wild-type, ARR2Pb.Stat3C, and PTEN
+/− mice but significantly ele-
vated levels in ventral prostate of ARR2Pb.Stat3C × PTEN
+/− mice
at 6 months (Figure 5). This increase was presumably due to increased
phosphorylation of endogenous Stat3, but we cannot rule out the
possibility that both endogenous Stat3 as well as the Stat3C transgene
underwent increased phosphorylation. In contrast, phospho-Akt was ele-
vated in prostate of ARR2Pb.Stat3C, PTEN
+/−, and ARR2Pb.Stat3C ×
PTEN+/− mice compared with wild-type mice with no statistical dif-
ference between the relative Akt phosphorylation level in the latter
two genotypes (see again Figure 5). The mechanism for the increased
phosphorylation of Akt in ventral prostate of ARR2Pb.Stat3C mice is
Figure 6. IHC analyses of Ki67, β-catenin, and E-cadherin in prostate of ARR2Pb.Stat3C × PTEN
+/− mice. Representative stained sec-
tions of normal tissue, hyperplasia, PIN, and adenocarcinoma of the ventral prostate from ARR2Pb.Stat3C × PTEN
+/−mice at 6 months
are shown. IHC staining was performed using antibodies against Ki67, β-catenin, and E-cadherin as described in Materials and Methods.
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not currently known at the present time. Recently, Iliopoulos et al. [50]
reported that Stat3 can regulate several microRNA, including miR21
that targets PTEN mRNA leading to reduced PTEN levels. Other
mechanisms may also be involved in the increased phosphorylation
of Akt in ventral prostate of ARR2Pb.Stat3C mice and remain to be
explored. Collectively, the data indicate that the combination of con-
stitutive Stat3 activation and PTEN loss (i.e., elevated Akt) led to signif-
icant further activation of Stat3 in the ventral prostate of the compound
transgenic mice. The elevated level of phospho-Stat3 observed in the
ventral prostate of ARR2Pb.Stat3C × PTEN
+/− mice at 6 months cor-
relatedmost closely with the progression of premalignant prostate lesions
to adenocarcinomas.
As noted in the Introduction, Stat3 activation plays a role in pros-
tate cancer growth and progression. Activation of Stat3 is observed in
human prostate tumors and prostate cancer cell lines and seems to be
involved in prostate cancer invasion and metastasis [10,11,45,51–54].
For example, an analysis of 45 adenocarcinomas obtained from radical
prostatectomy showed that constitutive Stat3 activation was found in
82% of the tumors compared with matched adjacent nontumor pros-
tate tissues. Furthermore, IHC detection of phospho-Stat3 showed
that elevated Stat3 activity was localized primarily in the tumor cells
of the prostate carcinoma specimens and correlated with more aggres-
sive tumors exhibiting higher Gleason scores [10]. Stat3 is activated
by phosphorylation of tyrosine and serine residues through upstream
kinases. Interleukins 6 and 11 (IL-6 and IL-11) signaling has been
shown to activate Stat3 in human prostate cancer and prostate cancer
cell lines [52]. For example, using LNCaP, TSU, PC3, and DU145
prostate cancer cell lines, Lou et al. [51] reported an elevated growth
stimulation by IL-6 accompanied by activation of Stat3 signaling.
Campbell et al. [52] have shown in an in vitro and an in vivo study
Figure 7. IHC analysis of NF-κB phosphorylation in the ventral prostate of the ARR2Pb.Stat3C, PTEN
+/−, and ARR2Pb.Stat3C × PTEN
+/−
transgenic mice. (A) Activated NF-κB (p65) was expressed in a small number of basal cells in normal tissue, hyperplastic, and PIN lesions
in all the transgenic lines. In contrast, more intense and widespread nuclear staining was observed in adenocarcinomas from the double
transgenic mice. (B) Magnification (×40) of phospho–NF-κB staining from a PIN (left) showing few cells with nuclear expression and an
adenocarcinoma (right) showing a dramatic increase in the number of stained nuclei from ARR2Pb.Stat3C × PTEN
+/− transgenic mice.
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that the IL-11 receptor system was upregulated in prostate carcinoma
and that it may be one part of a cytokine network that maintains Stat3
activated in these tumors. Recently, the Fer tyrosine kinase was shown
to cooperate with IL-6 to activate Stat3 in PC-3 cells [55]. The mech-
anism(s) whereby Stat3 activation is significantly upregulated in ventral
prostate of ARR2Pb.Stat3C × PTEN
+/− mice remains to be deter-
mined. One possibility could be through activation of NF-κB. As
shown in Figures 7 and W8, a relatively intense nuclear staining for
phospho-NF-κB was observed in adenocarcinomas from the ARR2Pb.
Stat3C × PTEN+/− mice. NF-κB activation occurs as a result of PTEN
loss through activation of both Akt and nitric oxide synthesis [56].
NF-κB regulates several cytokines, including IL-6 and IL-23 [56],
which could lead to further activation of Stat3 in ARR2Pb.Stat3C ×
PTEN+/− mice. This hypothesis is currently being tested.
Further evidence for cross talk or interaction between PTEN/Akt
and Stat3 signaling pathways is supported by studies in other sys-
tems. For example, Sun and Steinberg [44] reported that tyrosine
phosphorylation of Stat3 (Tyr705) was inversely correlated with ex-
pression of PTEN in vitro. Stat3 activation was found to be positively
regulated with mTOR signaling, whereas PTEN served as a negative
regulator of both Stat3 and mTOR signaling and was critical for can-
cer stem cell–like cell maintenance in MCF7 SP cells [46]. In hepa-
tocellular carcinoma cells, a simultaneous activation of the JAK/Stat,
PI3K/Akt, and Erk signaling pathways was reported to be involved in
promotion of invasion and migration [43]. Although the precise
mechanism(s) for interaction between these two pathways has not
been clarified to date, the growing body of data suggest a clear inter-
action between Stat3 and Akt signaling pathways in tumor develop-
ment and progression in several cancers, including prostate cancer.
Several mouse models are currently in use for the study of human
prostate carcinogenesis [57–59]. Mouse models with loss of PTEN
have a variety of preneoplastic and neoplastic lesions including hyper-
plasia, PINs, and adenocarcinomas. The development and morphol-
ogy of the prostate lesions in mice with PTEN loss depend closely on
the genetic background and on whether additional genetic changes
are present. For example, a recent study [36] has shown that PTEN
locus heterozygosity is fully penetrant for the development of prostate
adenocarcinoma when present on a C57BL/6 genetic background
compared with mixed genetic backgrounds [30,33] and an ICR ge-
netic background (see Table 1; this study). The histopathologic fea-
tures from normal tissue, hyperplasia, PINs to adenocarcinomas in
ARR2Pb.Stat3C × PTEN
+/− mice are similar to those observed in
other models where PTEN loss is coupled with additional genetic al-
terations. For example, the prostate phenotype in the p27Kip1−/−
mice, results only in mild hyperplasia [60–63]; however, when this
mouse is crossed with the PTEN+/− mice (Pten+/−/Cdkn1b−/−), the le-
sions in the prostate glands progress to the development of adenocar-
cinomas in ∼25% of the animals [37]. Another mouse model where
PTEN loss is coupled with another genetic change is the PTEN+/− ×
Nkx3.1−/− mice. Loss of Nkx3.1 leads to hyperplasia and PIN lesions
in the prostate of the mice [64]; however, when these mice are crossed
with the PTEN+/− mice (PTEN+/− × Nkx3.1−/−), mice develop high-
grade PIN and early carcinomas [38,65]. Both of these models to-
gether with the ARR2Pb.Stat3C × PTEN
+/− mouse model support
the hypothesis that heterozygous PTEN loss (and thus increased PI3K/
Akt signaling) cooperates with other genetic alterations to produce
prostate adenocarcinomas in mice.
In conclusion, we have shown that expression of a constitutively
active form of Stat3 (Stat3C) is associated with the development of
premalignant prostate lesions (i.e., hyperplasia and PIN) in the ven-
tral prostate of the ARR2Pb.Stat3C transgenic mice. Notably, when
the Stat3C transgene was expressed together with loss of PTEN (i.e.,
ARR2Pb.Stat3C × PTEN+/− mice), progression to adenocarcinomas
was observed that correlated with further up-regulation of activated
Stat3 (presumably endogenous Stat3) and NF-κB. These data dem-
onstrate that cooperation between Akt and Stat3 signaling results in
the development of prostate tumors in mice. We hypothesize that
Stat3C transgene expression leads to early preneoplastic changes,
whereas cross talk between the Stat3 signaling and Akt signaling
pathways is necessary for the progression from preneoplastic to neoplas-
tic changes in the ventral prostate of these mice. ARR2Pb.Stat3C ×
PTEN+/− mice represent a new in vivo model for studying the role of
Stat3 and Akt signaling in the progression of prostate cancer.
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Figure W1. H&E-stained sections of the ventral prostate from ARR2Pb.Stat3C mice at 12 months. Areas of normal tissue, hyperplasia,
and PIN lesions are shown. (A and B) Ventral prostate showing a single stratum of luminal epithelial cells with normal flat morphology for
quiescent glands (A) and typical cells with cylindrical shape in an active epithelium (B). (C and D) Ventral prostate from a 12-month-old
mouse showing luminal epithelial hyperplasia without cellular atypia (C) and with cellular atypia (D). The hyperplasia was characterized
by an increase in epithelial tufting but otherwise the appearance of the cells was relatively normal. (E and F) PIN lesions were charac-
terized by cell enlargement, karyomegaly, karyocytomegaly, nuclear atypia with apical localization, chromatin condensation, and the
presence of one or more prominent nucleoli. Also, a cribriform growth pattern, as well as the formation of many small intraluminal
glands, was noted. Magnifications, ×10.
Figure W2. Additional H&E-stained sections of lesions in the ventral prostate from ARR2Pb.Stat3C mice. (A and B) Areas of the ventral
prostate with mixed normal tissue and PINs with fusiform and cribriform patterns (4×). (C and D) The ×10 and ×20 magnifications of
a PIN lesion. Note that the nucleus in cells of this PIN lesion are adopting an apical position compared with a more basal position in the
normal cells. (E and F) Higher magnification (×40 and ×100) of the PIN lesions in the VP. This section shows the variety of shapes of the
dysplastic nuclei and cells. Cells also presented with karyocytomegaly and an increase in number and size of the nucleolus. Note the dif-
ference in the sizes of the nucleolus among cells as well as chromatin condensation and nuclear atypia.
Figure W3. Additional examples of invasive adenocarcinomas in the ventral prostate of double transgenic (ARR2Pb.Stat3C × PTEN
+/−)
mice. (A and B) Adenocarcinomas from the ventral prostate of a 12-month-old ARR2Pb.Stat3C × PTEN
+/− mouse. Note the widespread
local invasion of moderate- to well-differentiated tumor cells (×4). (C–F) Higher magnifications (×10) of adenocarcinomas from the ven-
tral. Circles in panels D, E, and F show areas of neovascularization inside of the neoplastic gland.
Figure W4. (A–D) Additional examples (larger magnification) of neoplastic glands with clear membrane disruption and stromal invasion.
Note also the formation of small intraluminal glands.
Figure W5. IHC staining for K14 and laminin in tissue from the ventral prostate of the ARR2Pb.Stat3C × PTEN
+/− mice. (A) K14 staining
of a normal gland (WT mouse) denoting a basal cell staining. (B) K14 staining of an adenocarcinoma from an ARR2Pb.Stat3C × PTEN
+/−
mouse. K14 was largely expressed in basal cells and in cells infiltrating the lumen of the neoplastic gland. In addition, K14 was ex-
pressed in some cells found in the stroma (arrows). (C–E) Laminin staining: pictures show a clear membrane disruption and adjacent
invasion in the affected glands (circles).
Figure W6. Composite picture showing IHC staining for the transgene (Stat3C) using antibodies to the Flag-tag and for phospho-Stat3
(using antibodies for phospho-Tyr705) in normal glands (both quiescent and active), hyperplasia, PIN, and ACs from ventral prostate of
the ARR2Pb.Stat3C × PTEN
+/− mice. Stat3C was expressed in the normal (active) glands and hyperplastic glands from the ventral pros-
tate of double transgenic mice. Staining was seen in both the cytoplasm and nucleus. Transgene expression (both cytoplasmic and
nuclear) was reduced in both PIN and ACs. In contrast, phospho-Stat3 (Tyr705) was primarily cytoplasmic in normal (active) and hyper-
plastic glands with strong nuclear staining in PIN and ACs.
Figure W7. Higher magnification (×40) from the previous composite images of Flag-tag (Stat3C) staining in normal (active) and hyper-
plastic glands (A and B) and nuclear phospho-Stat3 staining in PIN and adenocarcinomas (C and D).
Figure W8. Additional IHC analyses of VP from 6- and 12-month-old ARR2Pb.Stat3C × PTEN
+/− transgenic mice (n = 5) for phospho-NF-
κB (p65). Strong nuclear staining was observed in 100% (5/5 samples) of the adenocarcinomas from the double transgenic mice. (A–D)
Samples from four different mice (magnification, ×10). (E) Sample from another double transgenic mouse (magnification, ×20). (F)
Higher magnification (magnification, ×40) of the same sample shown in panel D.
